SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Business Wire
Prospective study published in Clinical Cancer Research shows that women 70 who tested Signatera MRD-negative could avoid surgery and remain progression-free AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a publication in Clinical Cancer Research showing that Signatera was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery.While pET can be an alternative to surgery for patients with early breast cancer, tools for risk stratification and monitoring have been limited. This prospective study enrolled 43 women, aged 70 and older, with stage 1-3 ER+/HER2- breast cancer who all elected to forgo surgery and receive pET. Patients were tested with Signatera at baseline (pre-treatment), and then every 3-6 months alongside standard imaging and physician assessment. Key results included:Pre-treatment (baseline) molecu
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera (NTRA) Launches Zenith Genomic Assay [Yahoo! Finance]Yahoo! Finance
- Natera Looks Compelling As Oncology Testing Momentum Keeps Building [Seeking Alpha]Seeking Alpha
- Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal CancersBusiness Wire
- Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis [Yahoo! Finance]Yahoo! Finance
- Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease DiagnosisBusiness Wire
NTRA
Earnings
- 2/26/26 - Miss
NTRA
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 4
- 3/20/26 - Form 144
- NTRA's page on the SEC website